LUPUS ACADEMY CHINA 2022
OPTIMIZING OUTCOMES AND PREVENTING DAMAGE IN SLE AND LUPUS NEPHRITIS

Meeting Chair: Sandra Navarra (Philippines)
27th February 2022: CST (UTC+8 Beijing) 15:00–18:55 hours

Session 1: SLE TREATMENT
Moderators: Sandra Navarra (Philippines) & Nan Shen (Shanghai, China)

15:00 SLE Treatment Challenges in China: A Case Based Review
Q&A and Discussion (15 Mins)
Nan Shen (Shanghai, China)

15:30 Targeting remission and low disease activity in SLE
Q&A and Discussion (15 Mins)
Andrea Doria (Italy)

16:00 Strategies for minimizing corticosteroid exposure in SLE
Q&A and Discussion (15 Mins)
Zahir Amoura (France)

16:30 Panel Discussion (15 Mins)
All

Session 2: MANAGEMENT OF LUPUS NEPHRITIS
Moderators: Sandra Navarra (Philippines) & Feng Yu (Beijing, China)

16:45 Lupus Nephritis Treatment Challenges in China: A Case Based Review
Q&A and Discussion (15 Mins)
Feng Yu (Beijing, China)

17:15 Debate: Management of Lupus Nephritis
The matter of the debate (10 mins)
Ronald van Vollenhoven (Netherlands)
Onno Teng (Netherlands)
Dimitrios Boumpas (Greece)

All lupus nephritis patients should be initially managed with both established standard therapies and the new generation drugs (20 mins + 10 mins rebuttal)

All lupus nephritis patients should be initially managed with established standard therapies alone (20 mins + 10 mins rebuttal)

Q&A and Discussion (30 Mins)
All

18:55 Close

Learning Objectives
- Illustrate case-based treatment challenges of SLE and lupus nephritis in China
- Explain best outcome measures for the optimal management of SLE
- Discuss best treatment strategies for preventing damage in SLE
- Demonstrate case-based treatment clinical practice challenges in lupus nephritis